Pages Menu
FacebookTwitterPinterestRss
Categories Menu

Orphazyme

Expanded Access Program for arimoclomol

.
Regan Sherman
Associate Director, Patient Advocacy Relations

res@orphazyme.com

.
CLINICALTRIALS.GOV LINK
_____________________________

 

Orphazyme Announces Early Access Program Availability in the U.S. for NPC

Following last week’s news of positive data from the open label extension period of phase 2/3 trial in Niemann-Pick Disease Type C, Orphazyme is thrilled to announce availability of an Early Access Program (EAP) for those living with NPC in the U.S.

CLICK HERE FOR COMPLETE ANNOUNCEMENT

.

Statement to the U.S. NPC Patient/Parent Community

A communication from Orphazyme to the US NPC patient/parent community has also been shared which provides some direction for how interested families can obtain information about the program.

CLICK HERE FOR FURTHER DETAILS

02/06/2020 jjb